{"id":1044,"date":"2021-05-27T10:52:46","date_gmt":"2021-05-27T10:52:46","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=1044"},"modified":"2021-05-27T10:52:46","modified_gmt":"2021-05-27T10:52:46","slug":"14-may-2021-interferon-alpha-2b-associated-with-improved-clinical-outcomes-in-patients","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/14-may-2021-interferon-alpha-2b-associated-with-improved-clinical-outcomes-in-patients\/","title":{"rendered":"(14 May 2021) Interferon alpha 2b- associated with improved clinical outcomes in patients"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p>Interferon-alpha-2b Aerosol Inhalation is Associated with Improved Clinical Outcomes in Patients with Coronavirus Disease-2019<\/p>\n<p>https:\/\/doi.org\/10.1111\/bcp.14898<\/p>\n<p class=\"\">A total of 1401 patients were enrolled, 852 (60.8%) patients received 5,000,000 U of IFN-alpha-2b via aerosol inhalation twice daily. The primary outcome was a composite measure consisting of mechanical ventilation, intensive care unit (ICU) admission, and death. A subgroup analysis was performed to investigate the impact of the IFN-alpha-2b initiation schedule on symptom onset.&nbsp; The risk probability for crude endpoints was lower in the IFN-alpha-2b group (3.8%) than in the non-IFN-alpha-2b group (9.3%, p &lt; 0.001). After adjusting the confounding factors, IFN-alpha-2b therapy achieved a reduction of 64% in occurrence of endpoint events (hazard ratio, 0.36; 95% confidence interval (CI), 0.21 to 0.62). In the subgroup analysis, compared with patients who received IFN-alpha-2b treatment 0-2 days after the symptom onset, the hazard ratio for endpoints was 2.2 (95% CI, 0.43 to 11.13) in patients who received the therapy 3-5 days after the symptom onset, 5.89 (95% CI, 0.99 to 35.05) in patients who received the therapy 6-8 days after the symptom onset, and remained at a high level thereafter.&nbsp; IFN-alpha-2b aerosol inhalation therapy may be associated with improved clinical outcomes in patients with COVID-19, and delayed IFN-alpha-2b intervention was associated with increased probabilities of risk events.&nbsp;<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Interferon-alpha-2b Aerosol Inhalation is Associated with Improved Clinical Outcomes in Patients with Coronavirus Disease-2019 https:\/\/doi.org\/10.1111\/bcp.14898 A total of 1401 patients were enrolled, 852 (60.8%) patients received 5,000,000 U of IFN-alpha-2b via aerosol inhalation twice daily. The primary outcome was a&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/14-may-2021-interferon-alpha-2b-associated-with-improved-clinical-outcomes-in-patients\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(14 May 2021) Interferon alpha 2b- associated with improved clinical outcomes in patients&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,30],"tags":[80],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/1044"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=1044"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/1044\/revisions"}],"predecessor-version":[{"id":1045,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/1044\/revisions\/1045"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=1044"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=1044"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=1044"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}